Story perspectives

Supreme Court Reviews Hikma-Amarin Skinny-Labeling Case

4/29/2026

25 5

Summary

Story summary

Supreme Court heard Hikma v. Amarin, a “skinny labeling” case between generic Hikma Pharmaceuticals and brand-drug Amarin.
Skinny labeling lets generics sell a drug for unpatented uses while other patents remain.
Amarin alleges Hikma marketed its generic as a version for patented uses, infringing Amarin’s patents.
Seventy scholars and the solicitor general defended Hikma, saying skinny labeling saved Medicare nearly $15 billion (2015-2021) and patients $8 billion after the 2016 generic launch.

1 of 1

Story summary

Supreme Court heard Hikma v. Amarin, a “skinny labeling” case between generic Hikma Pharmaceuticals and brand-drug Amarin.
Skinny labeling lets generics sell a drug for unpatented uses while other patents remain.
Amarin alleges Hikma marketed its generic as a version for patented uses, infringing Amarin’s patents.
Seventy scholars and the solicitor general defended Hikma, saying skinny labeling saved Medicare nearly $15 billion (2015-2021) and patients $8 billion after the 2016 generic launch.